Using PROTECT trial data, investigators assessed the possible benefit of early treatment vs active monitoring for cribriform-positive prostate cancer.
Cribriform-positive morphology was associated with a 3.6-fold higher risk for metastasis in patients with prostate cancer, and radiotherapy with neoadjuvant androgen deprivation therapy (ADT) was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results